Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s c...
- Open
- 10.580
- High
- 10.620
- Low
- 10.290
- Prev. Close
- 10.690
- Volume
- 721.99K
- Turnover
- 7.56M
- Avg Price
- 10.467
- Bid/Ask Ratio
- 70.94%
- Amplitude
- 3.09%
- 52wk High
- 36.259
- Volume Ratio
- 0.65
- Turnover Ratio
- 1.22%
Olema Pharmaceuticals Analyst Rating
View moreForecast & Rating
Aug 20, 2026Price forecast
$39.30276.80%
Forecast & RatingStrong buy
12analysts
- Strong buy75.00%
- Buy16.67%
- Hold8.33%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 13 at 03:42 PM
Olema Pharmaceuticals CFO Jason O’Byrne files initial beneficial ownership statement
- Market Beat · Aug 13 at 10:36 AM
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price
- PUBT · Aug 13 at 06:06 AM
Olema Pharmaceuticals names Jason O’Byrne CFO
- Market Beat · Aug 11 at 02:36 PM
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup
- benzinga_article · Aug 11 at 01:27 PM
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
- Tip Ranks · Aug 10 at 10:35 PM
Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained
